Navigation Links
Antidepressant Use May Boost Fracture Risk, From Harvard Women's,Health Watch

BOSTON, May 29, 2007 /PRNewswire-USNewswire/ -- Evidence is accumulating that depression is a risk factor for osteoporosis, reports the June 2007 issue of Harvard Women's Health Watch. A recent study found that people ages 50 and over who regularly took antidepressants called selective serotonin reuptake inhibitors (SSRIs) had double the rate of fractures as people not using such medications. Other research points to depression itself as a source of endocrine changes that can damage bone.

Whether the danger comes from depression, the drugs used to treat it, or something else, doctors are paying more attention to this association. During the 1990s, depression began to emerge as a possible cause of bone loss, rather than a result. Scientists studied women who didn't have osteoporosis symptoms or even know they had the condition. They found lower bone mineral density in those who were depressed. Moreover, the link was found in both younger women and women past menopause. Other studies have found a similar relationship, so investigators have been looking at hormones and brain chemicals potentially involved in both depression and bone loss.

Researchers working with an animal model found that depression triggers the release of noradrenaline, which interferes with bone-building cells. Moreover, they found that imipramine-a member of an older class of drugs called tricyclic antidepressants-reversed both depression and depression- induced bone loss.

It may be a long time before the depression-osteoporosis connection is fully clarified. In the meantime, Harvard Women's Health Watch suggests that you continue taking an antidepressant if you already use one; depression is a serious illness that can have profound consequences. You may also want to talk to your doctor about getting a bone density test, and make sure you get adequate calcium.


    Also in this issue:


    -- Update on treating 
'"/>




Page: 1 2

Related medicine technology :

1. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
2. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
3. FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications
4. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
5. New Cardioprotective Drug Could Provide Boost For Post-Bypass Surgery Heart Health
6. Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
7. Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter
8. FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer
Post Your Comments:
(Date:12/24/2014)... -   The issue: ... tests confirmed it contains two undeclared amphetamine-like drug substances ... distributor, Empire Health Distribution of Terrebonne, Quebec ... across Canada .  Jetfuel Superburn is ... and increased energy. What consumers should ...
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... and Pipeline Analysis, 4th Edition Now Available... -- DALLAS, September 28, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... SCOLR Pharma, Inc. (NYSE AMEX: DDD ... as the Chairman of its Board of Directors.  Johnson ... the Board.   Johnson previously served as ... Under Johnson,s leadership, Matrixx successfully developed and launched the ...
Cached Medicine Technology:Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 2Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 3Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 4Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 5Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 6Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 7Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 8Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 9SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 2SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 3
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... Dynavax Technologies,Corporation (Nasdaq: DVAX ) announced today ... present an overview of the,company at two investor conferences ... will present at the CIBC World Markets 18th Annual,Healthcare ... ET (5:35,a.m. PT). In addition, Ostrach will present at ...
... Inc. today,announced the initiation of a phase 1 ... treatment of hypertension. AR9281 is a "first-in-class,",orally-active inhibitor ... the treatment of hypertension. The trial will enroll ... the safety, tolerability,pharmacokinetics and pharmacodynamics for single ascending ...
... Nov. 1 Amira Pharmaceuticals, Inc. announced,completion of ... Amira,s,internally discovered oral drug candidate for the treatment ... also announced the start,of a Phase 1 trial ... targets the,same inflammatory response. AM103 and AM803 ...
... NAPLES, Fla., Nov. 1 MediaBrains Inc., a ... http://www.agingcare.com . The,website will focus on the needs ... for connecting caregivers with expert information,resources, products and ... Month. The caregiver market represents one of ...
... 1, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the,global ... Q3 2007 Financial Highlights - Product sales up 41% ... $608.7 million; - Net cash provided by operating activities ... growth now expected to be at least 30% (Q2 guidance: ...
... - An Innovative Approach to Preventing Kidney Damage during ... ... Systems Inc. (Amex: PLC ), a,company focused on innovative cardiac ... RenalGuard,System(TM) during Renal Week, the American Society of Nephrology,s 40th,Annual Meeting ...
Cached Medicine News:Health News:Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Agingcare.com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30
Both versions of the UltraSling II provide immobilization for rotator cuff repairs, capusular shifts, Bankhart repairs, glenohumeral dislocations/subluxation and soft tissue repairs/strains....
Unique V-lock strapping system prevents roll and shifting to provide secure shoulder immobilization...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Effective spinal bracing is a critical component ... surgical stabilization. The Aspen® Lumbosacral Bracing System™ ... provide a high degree of immobilization, unparalled ... patients . . . even if they ...
Medicine Products: